Venture investor, company operator, and serial entrepreneur joins governance team at leading nanotechnology company building a post-scarcity future
MENLO PARK, Calif.–(BUSINESS WIRE)–#FutureOfAbundance–Aether Biomachines, a nanotechnology company building a future of abundance, today announced the appointment of True North Venture Partners’ Erik Scher, Ph.D., to its Board of Directors. A distinguished leader with over two decades of experience in the technology industry, Dr. Scher will provide guidance to Aether’s team as they develop AI-driven nanotechnology to unlock novel materials, therapeutics, commercial products, and environmental strategies.
“We are thrilled to have Erik join our Board of Directors to support our efforts to push beyond what nature invented and build a new era of products that solve critical real-world problems,” said Pavle Jeremic, Founder and CEO of Aether Biomachines. “Erik’s background in chemistry and engineering will be instrumental to Aether as we work to custom engineer novel, natural proteins into general-purpose molecular assemblers.”
Dr. Scher is an Operating Partner at True North Venture Partners where he works in executive roles at portfolio companies supporting commercialization, strategic planning, and investment decisions. As a founder, board director, technical and commercial leader, and advisory board member for entrepreneurial companies across the energy, chemicals, advanced materials, and consumer product industries, he has helped invent, scale, and commercialize numerous novel technologies. Amongst his operational roles, Dr. Scher served as Chief Commercial Officer and President at Hyconix, and Chief Executive Officer and Chief Operating Officer at Siluria Technologies. He received a Ph.D. in Materials Chemistry from the University of California, Berkeley, and a bachelor’s degree in Chemistry from Rice University.
“I am excited to serve on Aether’s Board of Directors and look forward to working with Aether’s leadership team to further develop its one-of-a-kind nanotechnology platform to build a future of abundance,” said Erik Scher. “Aether’s mission and technology have incredible potential to improve global human health and end resource scarcity.”
Aether is building the world’s highest throughput robotic factory to custom engineer molecular assemblers that can synthesize new molecules from commonly found chemicals. Recently the company announced a partnership with Allonnia to design enzymes to sustainably remove harmful perfluoroalkyl and polyfluoroalkyl substances (PFAS) from the environment.
Dr. Scher joins Aether’s Board of Directors with Austin Che, Co-Founder of Ginkgo Bioworks; Shlomo Yanai, former CEO of Teva Pharmaceuticals; Stuart Peterson, Managing Partner and Founder at ARTIS Ventures; Ameena El-Bibany, Partner at ARTIS Ventures; and Pavle Jeremic, Aether’s CEO and Founder as well as Commercial Advisory Board members Thomas Ebeling, former CEO of Novartis, and Chris Varma, Founder and CEO of Frontier Medicines.
About Aether Biomachines
Aether is building a future of abundance for humankind in a post-scarcity world. Powered by one of the world’s highest throughput robotic protein expression and screening laboratories, the company is generating data on scales previously not possible to feed deep AI algorithms. Aether’s platform uses nanotechnology to custom engineer novel, natural proteins into general-purpose molecular assemblers that can synthesize new molecules from commonly found chemicals, unlocking materials, therapeutics, products and environmental strategies previously unimaginable. Visit www.aetherbio.com to learn more about how Aether is catalyzing the next industrial revolution.
Sarah de Crescenzo
Thermal for Aether Biomachines